Patient data and results of serum measurements in cystic fibrosis patients with and without allergic bronchopulmonary aspergillosis(ABPA)
| ABPA | Non-ABPA | |
| Patients | 12 | 36 |
| Age at study entry yrs | 10 (8–12) | 9 (7–14) |
| Males/females | 7/5 | 19/17 |
| Study duration months | 40 (35–80) | 40 (27–55) |
| Serum samples | 7 (4–12); 87+ | 5 (1–8); 178+ |
| FEV1 on study entry % pred | 73 (77–81) | 89 (72–99) |
| A. fumigatus in sputum# | 12 | 20 |
| P. aeruginosa in sputum# | 12 | 34 |
| Serum measurements | ||
| Total IgE IU·mL−1 | 965 (324–1961) | 59 (21–433) |
| Specific IgG to A. fumigatus kU·L−1 | 145 (66–244) | 51 (17–105) |
| Specific IgE to A. fumigatus RAST class¶ | 4 (3–5) | 1 (0–3) |
| rAsp f 1 EU·mL−1 | 128 (60–364) | 21 (6–59) |
| rAsp f 3 EU·mL−1 | 253 (99–739) | 37 (14–94) |
| rAsp f 4 EU·mL−1 | 23 (11–53) | 4 (1–12) |
| rAsp f 6 EU·mL−1 | 25 (8–67) | 3 (2–8) |
| TARC pg·mL−1 | 589 (465–673) | 232 (189–289) |
Data are presented as n or median (interquartile range) unless otherwise stated. FEV1: forced expiratory volume in one second; % pred: % predicted; A. fumigatus: Aspergillus fumigatus; P. aeruginosa: Pseudomonas aeruginosa; Ig: immunoglobulin; RAST: radioallergosorbent test; rAsp f: recombinant A. fumigatus allergen; EU: ELISA unit; TARC: thymus- and activation-regulated chemokine. #: at least one positive sample during the study period; ¶: 0–6; +: median (range) per patient; total number of samples.